Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum

Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market

Asia accounts for nearly two-thirds of lung cancer cases worldwide

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that the Hong Kong Intellectual Property Department has granted a patent for the Company’s proprietary platform technology for predicting the likelihood of lung cancer using flow cytometry and fluorescent markers to characterize cell populations in sputum.